Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLTENASDAQ:EWTXNASDAQ:IRONNASDAQ:LYEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$60.48+0.2%$61.42$43.70▼$86.53$1.92B-1.4447,119 shs83,537 shsEWTXEdgewise Therapeutics$14.30-1.2%$14.68$10.60▼$38.12$1.52B0.281.21 million shs692,055 shsIRONDisc Medicine$51.61+3.0%$47.22$30.82▼$68.73$1.73B0.73345,690 shs413,971 shsLYELLyell Immunopharma$8.69-9.3%$9.10$7.65▼$45.42$141.86M-0.2669,435 shs229,031 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio+0.20%+1.56%-10.12%-10.11%+21.81%EWTXEdgewise Therapeutics-1.17%-6.47%-1.99%-39.43%-11.62%IRONDisc Medicine+3.03%-3.91%+5.56%-1.21%+18.53%LYELLyell Immunopharma-9.29%-10.78%+5.98%-24.89%-79.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLTEBelite Bio2.8392 of 5 stars3.53.00.00.03.80.80.6EWTXEdgewise Therapeutics2.7172 of 5 stars4.41.00.00.01.53.30.0IRONDisc Medicine2.2174 of 5 stars3.52.00.00.02.12.50.0LYELLyell Immunopharma2.954 of 5 stars2.83.00.00.01.15.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLTEBelite Bio 3.00Buy$96.6759.83% UpsideEWTXEdgewise Therapeutics 2.78Moderate Buy$39.78178.17% UpsideIRONDisc Medicine 3.09Buy$96.7087.37% UpsideLYELLyell Immunopharma 1.50Reduce$20.00130.15% UpsideCurrent Analyst Ratings BreakdownLatest EWTX, LYEL, IRON, and BLTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025IRONDisc MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$118.006/16/2025IRONDisc MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.006/11/2025IRONDisc MedicineRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$89.006/5/2025EWTXEdgewise TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$48.005/15/2025BLTEBelite BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.005/12/2025IRONDisc MedicineBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $120.004/30/2025EWTXEdgewise TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$41.004/21/2025EWTXEdgewise TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$43.00 ➝ $43.004/16/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$20.00 ➝ $20.004/3/2025EWTXEdgewise TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$56.00 ➝ $52.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLTEBelite BioN/AN/AN/AN/A$4.72 per shareN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.84 per shareN/AIRONDisc MedicineN/AN/AN/AN/A$14.85 per shareN/ALYELLyell Immunopharma$60K2,144.98N/AN/A$26.21 per share0.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLTEBelite Bio-$36.14M-$1.36N/AN/AN/AN/A-32.07%-30.91%8/8/2025 (Estimated)EWTXEdgewise Therapeutics-$133.81M-$1.55N/AN/AN/AN/A-30.95%-29.45%8/6/2025 (Estimated)IRONDisc Medicine-$109.36M-$3.92N/AN/AN/AN/A-22.61%-21.07%8/6/2025 (Estimated)LYELLyell Immunopharma-$342.99M-$25.00N/AN/AN/A-514,649.22%-73.66%-60.99%8/6/2025 (Estimated)Latest EWTX, LYEL, IRON, and BLTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025LYELLyell Immunopharma-$3.80-$3.60+$0.20-$0.18N/A$0.01 million5/8/2025Q1 2025EWTXEdgewise Therapeutics-$0.45-$0.43+$0.02-$0.43N/AN/A5/7/2025Q1 2025IRONDisc Medicine-$0.99-$1.02-$0.03-$1.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLTEBelite BioN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLTEBelite BioN/A24.3124.31EWTXEdgewise TherapeuticsN/A20.9920.99IRONDisc Medicine0.0437.6537.65LYELLyell ImmunopharmaN/A7.497.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLTEBelite Bio0.53%EWTXEdgewise TherapeuticsN/AIRONDisc Medicine83.70%LYELLyell Immunopharma66.05%Insider OwnershipCompanyInsider OwnershipBLTEBelite Bio13.29%EWTXEdgewise Therapeutics23.20%IRONDisc Medicine4.24%LYELLyell Immunopharma22.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLTEBelite Bio1031.84 million27.61 millionNot OptionableEWTXEdgewise Therapeutics60105.20 million80.79 millionOptionableIRONDisc Medicine3034.63 million33.17 millionNot OptionableLYELLyell Immunopharma27014.81 million11.51 millionOptionableEWTX, LYEL, IRON, and BLTE HeadlinesRecent News About These CompaniesLyell Immunopharma Releases Data From Phase I/II Trial of CD19/20 Dual Targeting CAR T-Cell TherapyJune 20 at 11:52 AM | precisionmedicineonline.comLyell reports new clinical data from trial of large B-cell lymphoma therapyJune 18 at 11:58 AM | finance.yahoo.comLyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell LymphomaJune 17, 2025 | globenewswire.comShort Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Drops By 94.5%June 11, 2025 | marketbeat.comLyell Immunopharma Taps Shook as Chief Medical OfficerJune 11, 2025 | marketwatch.comLyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive AppointmentsJune 9, 2025 | globenewswire.comLyell Immunopharma (NASDAQ:LYEL) Upgraded by Wall Street Zen to "Hold" RatingJune 7, 2025 | marketbeat.comLyell Immunopharma to Participate in the Goldman Sachs Global Healthcare ConferenceJune 4, 2025 | globenewswire.comLyell Immunopharma (NASDAQ:LYEL) Shares Up 14.7% - Should You Buy?June 4, 2025 | marketbeat.comLyell Immunopharma (NASDAQ:LYEL) Hits New 52-Week Low - Here's What HappenedJune 2, 2025 | marketbeat.comShort Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Expands By 71.6%June 1, 2025 | marketbeat.comLyell Immunopharma trading halted, news pendingMay 31, 2025 | msn.comvenBio Partners LLC Makes New Investment in Lyell Immunopharma, Inc. (NASDAQ:LYEL)May 22, 2025 | marketbeat.comLyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025May 17, 2025 | finanznachrichten.deLyell Immunopharma Advances CAR T-Cell Therapy PipelineMay 14, 2025 | tipranks.comLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025May 13, 2025 | globenewswire.comLyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025May 1, 2025 | globenewswire.comLyell Immunopharma announces FDA granted RMAT designation to LYL314April 17, 2025 | markets.businessinsider.comWhy Lyell Immunopharma, Inc.’s (LYEL) Stock Is Up 7.22%April 16, 2025 | aaii.comLyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell LymphomaApril 15, 2025 | globenewswire.comCAR-T developer Lyell lays off 73 ImmPact staffers, shutters LA facility shortly after acquisitionApril 8, 2025 | fiercepharma.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings3 Tech Stocks You Can't Miss in This Market CycleBy Gabriel Osorio-Mazilli | June 17, 2025View 3 Tech Stocks You Can't Miss in This Market CycleEWTX, LYEL, IRON, and BLTE Company DescriptionsBelite Bio NASDAQ:BLTE$60.48 +0.12 (+0.20%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$60.50 +0.02 (+0.02%) As of 06/20/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Edgewise Therapeutics NASDAQ:EWTX$14.30 -0.17 (-1.17%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$14.68 +0.38 (+2.66%) As of 06/20/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Disc Medicine NASDAQ:IRON$51.61 +1.52 (+3.03%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$52.40 +0.79 (+1.52%) As of 06/20/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Lyell Immunopharma NASDAQ:LYEL$8.69 -0.89 (-9.29%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$9.10 +0.41 (+4.72%) As of 06/20/2025 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
